Lorenzo Gasperoni
Prato, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 50 publications
Trastuzumab deruxtecan plus pertuzumab as a substantial advancement in previously untreated patients with HER2-positive metastatic breast cancer.
Journal: European review for medical and pharmacological sciences
Published: September 01, 2026
Correction: Efficacy and safety of first-line osimertinib monotherapy versus osimertinib plus platinum-based chemotherapy or amivantamab plus lazertinib in metastatic EGFR-mutated NSCLC: an indirect comparison.
Journal: Frontiers in oncology
Published: May 17, 2026
Pirtobrutinib Monotherapy for First-Line Chronic Lymphocytic Leukemia: A Non-Anchored Indirect Comparison Using Reconstructed Patient-Level Data.
Journal: Hematology reports
Published: May 13, 2026
Inflammatory indexes as prognostic biomarkers in advanced triple negative breast cancer patients.
Journal: Frontiers in oncology
Published: May 08, 2026
Comparative Efficacy of First-Line Therapeutic Options for ES-SCLC: An Indirect Comparison Using IPDfromKM-Reconstructed Individual Patient Data.
Journal: Cancers
Published: May 07, 2026
Survival in unresectable hepatocellular carcinoma: Comparison of four treatments based on patients reconstructed from Kaplan-Meier curves of randomized trials.
Journal: World journal of gastrointestinal pharmacology and therapeutics
Published: February 27, 2026
Efficacy and safety of first-line osimertinib monotherapy versus osimertinib plus platinum-based chemotherapy or amivantamab plus lazertinib in metastatic EGFR-mutated NSCLC: an indirect comparison.
Journal: Frontiers in oncology
Published: February 02, 2026
Long-term outcomes of ALK inhibitors in metastatic ALK-positive non-small cell lung cancer: an updated indirect comparison using reconstructed patient-level data.
Journal: Translational lung cancer research
Published: January 18, 2026
Progression-Free Survival with PARP Inhibitors According to Clinical Risk in Patients with Ovarian Cancer: An Indirect Comparison Using Reconstructed Data.
Journal: Oncology research
Published: December 15, 2025
Comparative Analysis of Maintenance Treatments in Patients with Newly Diagnosed Advanced Ovarian Cancer After First-Line Platinum-Based Regimens.
Journal: Cancers
Published: September 24, 2025
Treatment of metastatic ALK-positive non-small cell lung cancer: indirect comparison of different ALK inhibitors using reconstructed patient data.
Journal: Frontiers in oncology
Published: January 25, 2025
Treatment Options for Advanced Non-Small Cell Lung Cancer After Failure of Previous Immune Checkpoint Inhibitors and Chemotherapy: Meta-Analysis of Five Randomized Controlled Trials.
Journal: Current oncology (Toronto, Ont.)
Published: November 09, 2024
Last Updated: 09/26/2026